While Tandem Diabetes Care Inc has overperformed by 1.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TNDM rose by 46.17%, with highs and lows ranging from $53.69 to $21.85, whereas the simple moving average fell by -9.52% in the last 200 days.
On December 02, 2024, Morgan Stanley Upgraded Tandem Diabetes Care Inc (NASDAQ: TNDM) to Overweight. A report published by Bernstein on November 06, 2024, Initiated its previous ‘Outperform’ rating for TNDM. Goldman also rated TNDM shares as ‘Neutral’, setting a target price of $46 on the company’s shares in an initiating report dated October 04, 2024. RBC Capital Mkts Initiated an Outperform rating on October 02, 2024, and assigned a price target of $65. Morgan Stanley initiated its ‘Equal-Weight’ rating for TNDM, as published in its report on August 22, 2024. Canaccord Genuity’s report from August 08, 2024 suggests a price prediction of $57 for TNDM shares, giving the stock a ‘Buy’ rating. Redburn Atlantic also rated the stock as ‘Buy’.
Analysis of Tandem Diabetes Care Inc (TNDM)
Further, the quarter-over-quarter increase in sales is 31.43%, showing a positive trend in the upcoming months.
One of the most important indicators of Tandem Diabetes Care Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -45.96% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.32, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and TNDM is recording 1.35M average volume. On a monthly basis, the volatility of the stock is set at 4.88%, whereas on a weekly basis, it is put at 4.94%, with a loss of -1.28% over the past seven days. Furthermore, long-term investors anticipate a median target price of $53.15, showing growth from the present price of $35.49, which can serve as yet another indication of whether TNDM is worth investing in or should be passed over.
How Do You Analyze Tandem Diabetes Care Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.75%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 112.33% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
TNDM shares are owned by institutional investors to the tune of 112.33% at present.
